Marinus Pharmaceuticals (NASDAQ: MRNS) and Zafgen (NASDAQ:ZFGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.
This is a summary of recent ratings and target prices for Marinus Pharmaceuticals and Zafgen, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Marinus Pharmaceuticals currently has a consensus target price of $18.75, suggesting a potential upside of 310.28%. Zafgen has a consensus target price of $20.00, suggesting a potential upside of 197.62%. Given Marinus Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than Zafgen.
Volatility and Risk
Marinus Pharmaceuticals has a beta of 2.6, suggesting that its share price is 160% more volatile than the S&P 500. Comparatively, Zafgen has a beta of -0.55, suggesting that its share price is 155% less volatile than the S&P 500.
Earnings & Valuation
This table compares Marinus Pharmaceuticals and Zafgen’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Marinus Pharmaceuticals||N/A||N/A||-$18.89 million||N/A||N/A|
Insider & Institutional Ownership
63.6% of Marinus Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.2% of Zafgen shares are owned by institutional investors. 4.6% of Marinus Pharmaceuticals shares are owned by company insiders. Comparatively, 23.7% of Zafgen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Marinus Pharmaceuticals and Zafgen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Marinus Pharmaceuticals beats Zafgen on 8 of the 9 factors compared between the two stocks.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.